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Abstract 
  
Background:    Several  difficulties  remain in formulating treatment  for   chronic    hepatitis  
B  (CHB), 350  million    people    are  chronically    infected   with   HBV,  Chronic  
infection    with   hepatitis  B  virus   accounts   for  an   enormous   burden   of  disease  
worldwide, including  up  to half   of   all   cases   of  cirrhosis, end   stage  liver  disease , and 
hepatocellular  carcinoma. 
 
Aim of the work:  To maximize    the  elimination  of    the  viral  infection    while 
minimizing or   preventing   damage  to   the liver cells and tissues and  development of viral 
resistance to more antivirals. 
 
Patients and Methods:  Eighty eight patients of chronic  hepatitis B virus infection with  
resistance  to  lamivudine  treatment  as  proved   by  quantitative   PCR (more than 200 IU/ 
ml). Their  age  between  (20-60)  years, (85 males, and 3  females)  were  selected    from  
the   National    Hepatology    and    Tropical     Medicine   Research Institute and were 
included in  this  study. The included  patients were two groups, the first  group  42  patients , 
were  receiving  Lamivudine,   plus   (Baraclude)  Entecavir (tablet 0.5mg / day)  treatment    
at    the  time  of  assessment. The  second  group  46 patients    were    receiving  ( Hepsera  
tablet 10 mg / day )  Adefovir   dipivoxil   plus lamivudine (tablet). 
All  the  patients  were  subjected  to  the  following  : thorough   history  and clinical 
examination, abdominal  ultrasonography  and collection of blood samples for routine liver 
and kidney function investigations  and  serological   assay  for HBsAg, HBsAb, HBeAg, 
HBeAb, HBcAb quantitative HBV DNA (PCR).  
 
Results: Our  results  revealed   significant differences  between the  two groups of  patients  
of  CHBV  infection,  resistant  to Lamivudine  drug,  the  first  group  were higher  in  
response to  a  combination  between Lamivudine + (Baraclude) Entecavir, than    the   second   
group   who   were  receiving  Lamivudine + (Hepsera)  Adefovir dipivoxil  combination 
therapy. 
 
Conclusion:  Our    study  concluded    that    the  clinical  benefit  is  apparent    with  high 
percentage  after  a     combination   regimen  using Lamivudine  +  Entecavir  than  a 
combination  regimen  using  Lamivudine + Adefovir  dipivoxil  for  the treatment of resistant   
chronic  hepatitis    B  virus   who   were  treated   with  Lamivudine    only before. 
 
Recommendations: Optimal management of chronic hepatitis B,that  may  require  
long-term   and   sometimes   lifelong   treatment   to maintain its clinical   benefit   is 
challenging. It  is  important  to  initiate  treatment  with  a  drug    that  has  the  least  
potential  for  induction of  drug   resistance  as  sequential  monotherapy  which  may result  
in selection  of  multidrug resistant HBV mutatants. 
 
Key words:  A combination anti-HBV, Antiviral drug resistance, Nucleos(t)ide analogues, 
Lamivudine, Entecavir,  Adefovir dipivoxil. 
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Introduction 
 
Antiviral  drug    resistance  is  a  major 
limitation  to  the  long-term  use  of  
nucleos(t)ide analogue therapy (Lok, et al., 
(2007).  The  first    manifestation  of  
antiviral  resistance  is  virological   
breakthrough, which   is  defined  as  an  
increase  in  serum  HBV DNA by  more  
than 1  log from nadir or the redetection of 
HBV  DNA.    Serum    HBV  DNA  levels  
tend  to   be low   initially because  most 
antiviral    drug-resistant  mutants    have 
decreased    replication    fitness    compared  
to  the  wild-type  virus  but  compensatory  
mutations   that   can  restore  replication 
fitness  frequently    emerge    during  
continued  treatment    leading      to  a  
progressive increase in serum HBV DNA 
levels (Lok, 2011).  
 Entecavir    is    a    nucleoside    analogue 
(more  specifically,  a  guanine  analogue)  
that inhibits   reverse  transcription,  DNA  
replication   and   transcription  in   the    
viral  replication  process.  The  drug's 
manufacturer  claims  that  Entecavir  is 
more  efficacious  than  previous  agents 
used to treat hepatitis B (Lamivudine and 
Adefovir) {Sims   and Woodland, 2006). 
Adefovir  dipivoxil  (Hepsera)  is  a 
nucleotide  analogue  of  adenosine 
monophosphate  ,  which  can  inhibite 
reverse transcriptase and DNA polymerase 
activity  {Heathcote,  et  al.,  (1998)  & 
Glison,  et  al.,  (1999)&  Tsiang,  et  al., 
(1999)}.    Adefovir    dipivoxil      has  been  
evaluated  as    primary    monotherapy  for 
patients  with  chronic  hepatitis  B  and  in 
patients  who   developed   resistance  to   
lamivudine , it  was   approved   by    FDA 
(Marcellin,  et  al.,  (2003)&  Zeng,  et  al., 
(2006).  
Currently    approved    nucleos(t)ide  
analogues  for the treatment of hepatitis B 
have very    little or    no direct    inhibitory  
effect    on      cccDNA.  The  resistance  of  
cccDNA  to  treatments  that  act  primarily 
through inhibition  of reverse  transcription 
of pregenomic  RNA  and     the  long  half-
life  of  infected  hepatocytes  (and  hence 
cccDNA) account  for the  high  rate  of  
viral    relapse  when    treatment  is 
stopped.(Ganem and Prince, 2004). 
HBV  is    not    directly  cytopathic  .  The  
pathogenesis of   HBV-related liver  injury 
is  determined    by    the    interactions  
between  the  virus and  the  host  immune   
response  (Guidotti  et  al.,  2006).     
Quiescent  or  inactive  disease   indicates  
that  the  virus   is suppressed by the host 
immune response , In persons with chronic 
HBV  infection  ,  the  different  phases 
represent changes in  balance between  the 
host  immune  response  and  HBV 
replication.  In    chronically    infected  
individuals,  the    T-cell    responses  are 
weak and  poorly functional (Ferrari, et al., 
1990).  HBV-specific  T-cells  are 
maintained  in  a  dysfunctional    state    but 
not  deleted .  Increase in HBV-specific T-
cell responsiveness has been observed  in 
patients  who  undergo    spontaneous  or 
treatment-related  HBeAg  seroconversion 
(Rehermann, et al., 1996).  It  should  be  
noted  that  while  the   host immune in 
patients with chronic HBV infection  may 
be  ineffective  in  viral  clearance,  it  can 
mediate liver damage (Maini et al., 2000). 
Thus,  the  immune  response  can  be  a 
double-edge sword. 
HBV  has  been  classified  into  eight 
genotypes  (A-H)  based  on  nucleotide 
sequences  with  varying  distribution  in 
different  geographical  regions,  HBV 
genotypes  may    play  a    role  in  
determining  the  activity  and  risk  of 
progression  of  liver  disease(Fung  et  al  ., 
2004).  Mutations  in  the  precore  and  
core    promoter    regions  are  the  most 
common  naturally    occurring    HBV  
mutations,  this  mutation  results  in  a 
premature  stop  coden,  thus    preventing  
the  production    of  HBeAg.  It  is  most 
frequently found in association with  HBV 
genotype    D,  and  to  a  lesser  extent  in 
genotypes  A,  F  or  H.(  Carman  et  al., 
1989). 
 
Patients and Methods 
 
Eighty  eight  patients with   chronic  HBV   
infection      resistant   to    lamivudine  
treatments  proved   by    quantative  PCR, 
their age between (20-60) years, ( 85 male 
and 3 females ), were  selected   from    the  
National   Hepatology     and     Tropical 
Medicine    Research    Institute    to  be 
included  in the study  with  exclusion  of  
other chronic diseases or pregnancy.  Saadia Farid and Samya sweilam 
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The  included  patients  were  two  groups, 
the    first  group    42    patients    were  
receiving  lamivudine,    +    Baraclude  
(Entecavir)    and   the   second   group  46   
patients      were  receiving    lamivudine    +  
Hepsera  (Adefovir dipivoxil) at   the  time   
of assessement.    All  the  patients  were  
subjected    to    the    following  :  through  
history    and    clinical  examination,  
abdominal    ultrasonography    and  
collection    of  blood    samples  for  the 
routine    investigations      ALT,      AST,  
alkaline    phosphatase,     bilirubine,  
albumine,  CBCs,  serum  creatinine  and 
serological  assay  for  the  quantative 
PCR(HBV  DNA),the  patients    examined  
regularly  every  3  months  in  cases  of 
cirrhosis and every 6 months in cases  with  
liver free from  cirrhosis,10 ml of venous 
blood samples were obtained from    each   
patients    by    sterile  venipuncture  in  
dry    sterile  vacuatainers.      After 
centrifugation,  the serum  was   tested  for 
HBsAg, HBsAb, HBeAg, HBeAb, HBcAb 
were    done    by    Elisa    Technique.  All 
patients  were  tested  by  third generation 
Elisa, using  Kits  from (Dia Sorin Italy) 
HBsAg    lot  Number : 0370680 A / I,   
HBsAb  lot  Number  :  9230560    A  /  2,    
HBeAg    lot  Number :  0600340 A  / 1,       
HBeAb   lot Number : 0490370 B, HBV 
DNA was  quantitated  in  all  sera  using  
Real time  PCR (Strata  gene,  Taq  Man  
Gene  Expression  (Applied – Biosystems 
- Germany).   Lot Number : 139282089. 
The  kit  threshold  limit is 8.8 / IU / ml. 
 
 Statistical analysis :  Analysis  of  data  
was  done  by IBM computer using   SPSS 
(Statistical  program  for  social  science 
version  12)  as  :  Description      of   
quantitative  variables  as  mean,  SD  and  
range  &  Description  of    qualitative  
variables  as  numbers and percentage & 
Chi-  Square  test  was  used  to  compare 
qualitative  variables    between  groups  &  
Fisher  exact  test  was  used   instead of 
chi-square  when  one  expected    cell  less    
than  or  equal  5.  This  was  expressed  as   
probability  of      value      (P  value)  the 
difference  was  considered  significant  if  P 
value < 0.05. 
 
Results 
 
The    study    included    88    patients,  both  
males   and   females,  of  CHBV infection 
, resistant   to lamivudine   drug,  the  first  
group    (42)    patients    are    using    
Baraclude (Entecavir) + Lamivudine   and  
the      second      group  (46)    patients    are 
using Hepsera (Adefovir dipivoxil), for 48 
weeks. 
We    found    that  :  There'  s  no  statistical 
significant    difference  that  could    be 
detected  between    both    groups    as   
regarding    quantitative    (PCR)    HBV  
DNA      by  using  Chi-Square  test.  (p  > 
0.05) table (1), Graph (1).  
 
Table  (2):  illustrates  the  comparison  
between    both    groups    as  regard  to 
response to   a    combination    anti-HBV  
regimen.    The   responder   were   higher    
among  Baraclude  +  lamivudine    group    
than      Hepsera    +    lamivudine    with   
statistically    significant      difference 
between  both  grouped    by    using  Chi-
Square test. ( P < 0.001) Graph  (2). 
 
Table  (3):  Shows  the  comparison  
between  both  groups  as  regard 
seroconversion.    Ther's  no    statistically  
significant    difference    between    both  
groups  using  Fisher  exact  test  (P>  0.05) 
table (3), Graph (3). 
 
Table (A) Illustrate HBV RNA results before and after treatment : 
 
Hepsera group  Baraclude group  HBV DNA (Quantitative 
value) 
> 200 IU   >2 ,000,000 IU  Before treatment 
14 (patients) BDL 
8 (patients) < 200 IU 
1 (patient) < 500 IU 
 
23 (patients) BDL 
10 (patients) < 200 IU 
1 (patient) < 500 IU 
 
After treatment 
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 Below detection limit estimated as 8.8 IU / ml.* 
 
 
Table (1) Comparison between both groups as regard HBV DNA 
 
P   X
2  Hepsera  
N=46 
Baraclude  
N=42 
Variable 
HBV-DNA load  
>0.05 
NS 
0.3  14(30.4%)  23(54.7%)  Below detection  
8(17.4%)  10(23.8%)  <200 IU/ml 
1(2.1%)  1(2.3%)  200-500 IU/ml 
 
This table shows no   statistically significant difference could be detected between both 
groups as regard HBV  DNA by using chi-square test  
 
 
Below detection  <200 200-500
0
10
20
30
40
50
60
Baraclude Hepsera 
 
 
Graph (1) : Illustrate the HBV DNA IU/ml results in the sum of the two studied groups, 
according to chi-square results. 
 
 
Table (2) Comparison between both groups as regard the response to treatments by PCR 
results below detection limit in the responder group. 
 
P   X
2  Hepsera  
N=46 
Baraclude  
N=42 
Variables  
<0.001 
HS 
9.2  23(50%)  34(80.9%)  Responder  
 
23(50%)  8(19.1%)  Non responder 
 
 
This table shows  that non responder were higher among hepsera group with    statistically 
significant difference  between both groups by using chi-square test. 
  Saadia Farid and Samya sweilam 
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Graph (2) Illusrate that the responder were higher among Baraclude  group  by PCR results 
below detection limit, according to chi-square test results. 
Responder  Non responder
0
20
40
60
80
100
Baraclude Hepsera 
 
 
Table (3):  Comparison  between both groups as regard seroconversion of HBeAg (+ ve) into 
HBeAg (- ve). 
 
P   Hepsera  
N=46 
Baraclude  
N=42 
Variables  
>0.05 
NS 
43(93.5%)  39(92.9%)  No conversion 
 
3(6.5%)  3(7.1%)  Seroconversion 
 
 
This table shows  no    statistically significant difference  between both groups by using 
Fisher exact  test 
 
Graph (3) Illustrate seroconversion in the sum of the two studied groups. 
 
No conversion Seroconversion
0
20
40
60
80
100
Baraclude Hepsera 
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Discussion 
 
The aims of  hepatitis B treatment  are  to  
achieve  sustained suppression  of   HBV 
replication    and    remission    of    liver 
disease  .  The  ultimate  goal  is  to  prevent 
cirrhosis,  liver      failure    and    HCC.  
Parameters   used      to    assess    treatment    
response        include  decrease  in  serum  
HBV DNA, loss  of   HBsAg   with  or  
without    seroconversion    to  anti-HBs,  
normalization   in   serum   ALT,   and   
improvement   in   liver   histology { Lok, 
(2011)}.        The      most      important   
mutation   associated   with   resistance   to 
Lamivudine  is  a  substitution    of  
methionine  for  valine   or  isoleucine  (M 
204 V/ I)  in  the   Tyrosine-methionine-
aspartate  (YMDD)  motif.   The  M204 I   
but   not  the M204  V mutation is also  
associated  the  rt A 181 T  mutation  has 
also  been    shown  to    be  associated  with 
lamivudine  resistance.  {Tenney  ,  et  al., 
(2009)}. 
This  work  was  conducted  to  the  serum  
levels  of  ALT,  AST,  ALP,   albumin, 
bilirubin,  creatinine,  CBCs  (  Hb,  WBCs, 
platelets) in compensated chronic hepatitis 
B  virus  infection    after    treatment    and  
find out    the   possible   correlation    with  
HBeAg,  HBeAb,  HBsAb,  HBV  DNA 
(Quantitative). 
We  found  in  our  study  that  there  is  no 
significant      difference  in    between   
patients  who    were    receiving  Baraclude  
0.5 mg / dl /day or  who were  receiving  
Hepsera 10 mg / day   plus   Lamivudine  
100  mg    /    day    for      48    weeks   as   
regard  quatitative (PCR)  HBV DNA   at   
time   of   assessments.   Several   studies   
{ Lia Chien, et al.,(1998) & Dienstag, et 
al., (1999) &  Marcellin, et al., (2003)  &  
Chang, et al., (2006) &Lai et al., (2007)  &  
Macellin et al., (2008)} showed   that  the  
incidence    of  HBV  genotypic    antiviral  
resistance  varies   from  (0-25 %)  at  1- 
year  to   1-70 %   at  5  years. Tenney, et 
al.,  (2009)    found    that      resistance    to  
Entecavir  appears  to  occur  through   a   
two-  hit  mechanism.     Selection    of    
rtM204  V/  I    mutation    decreases   
susceptibility      of      the    virus      to    
Entecavir        slightly.    Additional   
mutations    at positions   184,  202  or   
250    are    necessary    for        the  
manifestation    of    entecavir    resistance.   
Decreased   activity   of    Entecavir   in    
viruses     with    rtM2o4 V / I   mutation   
explains  why   the  rate    of  Entecavir   
resistance    is   so    much   higher in    
patients    with    prior      Lamivudine   
resistance.  Tenney,  et  al.,  (2009)   
explained  that      mutations    associated   
with   resistance   to  Adefovir   include  
substitution   of Aanine for Threonine  or 
Valine  (rt  A  181  T  /  V)    and      a  
substitution  of  Asparagine for  Threonine  
(rt N 236 T).  These  changes   are  also  
associated    with      a    reduced   
susceptibility  to   Tenofovir.  This results 
correlated with  our study. 
In    the  present    study,  we    found    that  
there's  54.7 %  of  patients  with  HBV 
DNA serum load below detection limit in 
patients  who  were  using  Baraclude  + 
Lamivudine after 1 year,  and  30.4 %  in  
patients    who    were    using      Hepsera  + 
Lamivudine  .  Lai  Gane,  et  al.,  (2007)  &  
Marcellin, et al ., (2008) &  Hadziyannis, 
et al., (2003), found  that  a 1- year  course  
of    nucleo(t)ide  analogues    resulted  in 
extremely  high      rates    of  undetectable   
serum   HBV DNA  (51-93 %).    Lai, et 
al., (1998)   &  Dienstag, et al., (1999)  &   
Macellin, et al., (2003)    &   Chang, et al., 
(2006)  &  Lai, et al., (2007) & Marcellin, 
et al.,  (2008)   explained    that       a   1- 
year        course      of      nucleos(t)ide  
analogues    resulted  in  very  high  rates  of 
undetectable  serum   HBV DNA  (21-76 
%) . Sheman, et al., (2006) found that the 
magnitude  of  viral  load  reduction 
observed after 48 weeks of Entecavir (was 
5.08 log 10  copies / ml).  Peters, et al., 
(2004)    added  that  the  level    of    HBV 
DNA    suppression    also    compared   
favorably   to  that   reported    in  patients  
with    Lamivudine-resistant  HVB  
receiving   Adefovir  in  which  the   mean 
reduction   in  HBV DNA  was  4.00  log  
10  copies  /  ml    after  1  year    of  
treatment. These results are  in  agreement  
with  our study  results. 
lok  ,  (  2011)    observed    that  HBV 
nucleo(t)ide    analogues    Entecavir, 
Telbivudine  and  Tenofovir  have  more  
potent  antiviral    activity    followed     by   
Lamivudine  and    then    Adefovir.  Saadia Farid and Samya sweilam 
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Guangbi,  et  al.,  (2007)    explained    that   
Entecavir  treatment  for  48    weeks  
achieved   consistent   mean  reductions  in  
HBV DNA  in   both   patients infected 
with  HBV  genotypes  B(  -  4.96  log  10 
cpies / ml ) and C ( - 5.12 log 10 copies / 
ml  ).  Among  patients  who  received  48 
weeks  of    Entecavir    treatment,  the 
proportion  achieving      HBV  DNA  <  0.7  
MEq    /    ml    was  74  %    and    the    
proportion  achieving HVB DNA <  300  
copies / ml  by  PCR assay was 27 %.  Our 
study  revealed  that    the  responder  were   
higher    among        Baraclude      +   
Lamivudine    group    (80.9  %)    than 
Hepsera  +  Lamivudine  ( 50 %)   with   
statistically    significant      difference,     
these results   in  agreement   with    Anna 
Lok    whom    found  that  Entecavir  and 
Tenofovir  are  associated        with        the  
lowest      rate    of      drug      resistance,  
followed    by        Adefovir,  Telbivudine 
Lamivudine . 
Lai et al., (1998) & Dienstag, et al., (1999) 
& Macellin, et al., (2003) & Chang, et al., 
(2006) & Lai, et al., (2007) & Marcellin, 
et al., (2008)  postulated  that  a  1- year 
course    of    nucleos(t)ide    analogues  
resulted in very high rates of undetectable 
serum  HBV  DNA  (21-76  %)  and 
histological improvement (49- 76 % ), but 
only  12-22  %  of  patients    achieved  
HBeAg  seroconversion  and  only 0-3 % 
lost HBsAg.   Yao et al., (2007) observed 
that  among  HBeAg  (+)  patient    enrolled 
on  Entecavir,  the  rate  of  HBeAg  
seroconversion  after  1 year of  treatment   
was  low (6 %).  Sheman,  et al., (2006) 
explained  that  Furthermore,  lower 
serologic  response  rates  in  patients  who 
are refractory  to  Lamivudine  are to be 
expected  given  the  likelihood    that  
patients  who have remained HBe Ag (+) 
despite  prior  Lamivudine  treatment  may 
have  a  decreased  ability  to  mount  an 
immune-mediated  seroconversion 
response. These finding suggest that  long-
term  therapy    may    be    needed    to  
achieve    HBeAg    seroconversion    in  the 
Lamivudine      -  refractory    patients   
population.     In      our    study   
seroconversion    in  Baraclude    +   
Lamivudine   group    7.1 %   and    in    
Hepsera + Lamivudine   group (6.5 %). 
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عوجلا   ريفلل هيراقعلا تاداضولا نيب اه و ًب ًئابىلا يذبكلا س  
سإب باهتللاا جلاعل رخا راقع عه نيدىيفهلالا راقع ماذخت  
  ظقف نيدىيفيهلالل مواقولا ًب ًئابىلا يذبكلا  
 
س  ذيرف هيذع ( هنطىتولا نسق )    ,  نليىس هيهاس ( هيىيحلا ءايويكلا نسق )  
طٕحًنا عاشيلاا ٔ ذبكهن ٗيٕقنا ذٓعًناب ُّ .  
 
 
هيفلخلا   : ِذيذع تابٕعط     ثهظ   ٗف   ي  بآحنلاا ةدناع   ٗب ٍيزًنا ٖذبكنا  , 350    ٌَٕاعي ضخش ٌٕيهي
ٗب ٗئابٕنا ٖذبكنا بآحنلاا ٍي  , ٗهيظفج ٌايب   ءاشَلإا ذلاطلإ    ساشحَلاا  عئار عشًهن  ىيسدنا أبعهن  ,
 تلااح فظَ  لداعي  اي مًشي  ( فيهحنا  , ذبكنا عاشيأ ٗف ّيئآُنا محاشًنا ,   ذبكهن ّيَاطشسنا واسٔلأا ٔ )  
 
ثحبلا نه فذهلا  :  ذحنا ٗنإ لٕطٕناب ٗب ٗسٔشيفنا ءابٕنا ٍي ضهخحنا ٗف ًٗظعنا ّيآُنا ٗنا لٕطٕنا
ا  عًُب ٔأ ّن َٗدلأ  ( سٔشيفهن ّئاقًنا ساشحَإ ٔ ّيذبكنا ّدسَلأا ٔ ايلاخنا فهج .)  
 
ثحبلا ةقيرط  :  دذع ّساسذنا ثهًش 88   ب ٍيباظًنا ٗضشًنا ٍي ضخش  ٔ ٗب ٗئابٕنا ٖذبكنا بآحنلاا
 اي ىْساًعأ ظسٕحي ٔ وذناب ٖدذعنا سأ ٗس ٗب لا ةديحَ سايقب ِذحٔ ٍيدٕفييلانا ءأذن ّئاقًنا تأر
 ٍيب ( 20 - 60 )   اياع    ٗنإ ٍيًسقي ُّطٕحًنا عاشيلأا ٔ ذبكهن ٗيٕقنا ذٓعًنا ٗضشي ٍي ِاقحُي تاُيعنا
ٗنٔلأا ٍيحعًٕدي  :  دذع 42   ٍي     ٗضشًنا     ٌٕدناعي ٔ   صاشقأب    ( ٍيدٕيفييلانا   صشق     100    ىدي  /  وٕينا
 + دٕهكاسابنا   صشق   5 ٔ .    ىدي  /  وٕينا )   ىْدذع ٔ ّيَاثنا ّعًٕدًنا ٔ     46   ٍي     ٗضشًنا      ٍيدناعًنا  (
 صشق ٍيدٕيفييلاناب 100   ىدي  /  وٕينا  +  صشق اشيسبيٓنا 10    ىدي  /  وٕينا )  .   إعضخ  ٗضشًنا عيًخ
  زخأ عي  ّيبطنا  صٕحفهن  عاشيلأا داعبحسإ عي ذبكنا ٗهع ّيجٕظنا تاخًٕنا مًع ٔ ّيجازنا ِشيسنا
ٖشخلأا ُّيزًنا ,    تاُيع زخأ ىج ذق ٔ  تاششؤًهن ٗخٕنٔشيسنا ّيُيجٔشنا ثهطٕحفنا مًعن ٗضشًهن وذنا
ٍيُيجايشكنا ةبسَ سايق ٔ ٖدذع سأ ٗس ٗب مًع عي ٗب ّيذبكنا .  
 
جئاتنلا  : خٔ ٍع ّساسذنا ِزْ حئاحَ تشفسأ ذقن  ّبادحسلإا ِزْٔ ٍيحعٕدًنا احهكن ّيكيُيهكإ ّبادحسإ دٕ
 ّعًٕدًنا ٗف َايبسَ قٕفج  ٍيدناعًنا ٗنٔلأا ( ٍيددٕيفييلااب + دٕهكاسابنا  )  ةبسُب 80.8    %  ,  ّعًٕدًنا ٍع
 ٍيدناعًنا ّيَاثنا ( ٍيدٕيفييلااب  + اشبسبيٓنا  )  ةبسُب 50    %  سٔشي ذعب 12    دٕخٔ وذع عي جلاعنا ٍي شٓش
ُيهكإ تافعاضي ٖأ ّيكي .  